Novo, Sandoz Reach Deal Over Generic Prandin

Law360, New York (December 17, 2010, 1:15 PM EST) -- Novo Nordisk Inc. has agreed to drop infringement allegations against Sandoz Inc. over two claims of a patent for diabetes drug Prandin, in exchange for Sandoz's admission that it infringed three other claims.

The agreement, signed Thursday by Judge Paul G. Gardephe in the U.S. District Court for the Southern District of New York, stipulates resolution on all five claims of Novo-held U.S. Patent Number 6,677,358, the only patent asserted in the suit.

The '358 patent, titled “NIDDM regimen,” describes a short-acting oral hypoglycemic agent used...
To view the full article, register now.